{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:48:23Z","timestamp":1772628503567,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40261-020-00963-x","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T21:02:54Z","timestamp":1597093374000},"page":"897-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-1727","authenticated-orcid":false,"given":"Bruno","family":"Charpiat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bleyzac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"963_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5029","author":"A Potteg\u00e5rd","year":"2020","unstructured":"Potteg\u00e5rd A, Kurz X, Moore N, Christiansen CF, Klungel O. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020. https:\/\/doi.org\/10.1002\/pds.5029.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"963_CR2","doi-asserted-by":"publisher","unstructured":"Marks D. Time to halt the overprescribing of proton pump inhibitors. Clin Pharm. 2016. https:\/\/doi.org\/10.1211\/CP.2016.20201548. Available from: https:\/\/www.pharmaceutical-journal.com\/20201548.fullarticle. Accessed 9 Aug 2020.","DOI":"10.1211\/CP.2016.20201548"},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.3390\/ijms20236031","volume":"20","author":"TC Martinsen","year":"2019","unstructured":"Martinsen TC, Fossmark R, Waldum HL. The phylogeny and biological function of gastric juice-microbiological consequences of removing gastric acid. Int J Mol Sci. 2019;20:6031. https:\/\/doi.org\/10.3390\/ijms20236031.","journal-title":"Int J Mol Sci"},{"key":"963_CR4","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1099\/0022-1317-66-12-2725","volume":"66","author":"C Weiss","year":"1985","unstructured":"Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer and acidic gastic juice. J Gen Virol. 1985;66:2725\u201330.","journal-title":"J Gen Virol"},{"key":"963_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s005350200003","volume":"37","author":"Y Hayase","year":"2002","unstructured":"Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. J Gastroenterol. 2002;37:101\u20135.","journal-title":"J Gastroenterol"},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-017-0519-y","volume":"37","author":"L Fisher","year":"2017","unstructured":"Fisher L, Fisher A. Acid-suppressive therapy and risk of infections: pros and cons. Clin Drug Investig. 2017;37:587\u2013624. https:\/\/doi.org\/10.1007\/s40261-017-0519-y.","journal-title":"Clin Drug Investig"},{"key":"963_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1017\/S0950268817000528","volume":"145","author":"C Prag","year":"2017","unstructured":"Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect. 2017;145:1617\u201323.","journal-title":"Epidemiol Infect"},{"issue":"11","key":"963_CR8","doi-asserted-by":"publisher","first-page":"e1916205","DOI":"10.1001\/jamanetworkopen.2019.16205","volume":"2","author":"AM Vilcu","year":"2019","unstructured":"Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open. 2019;2(11):e1916205. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16205.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"963_CR9","doi-asserted-by":"publisher","first-page":"eaao4966","DOI":"10.1126\/sciadv.aao4966","volume":"3","author":"J Zhou","year":"2017","unstructured":"Zhou J, Li C, Zhao G, Chu H, Wang D, Hoi-Ning Yan H, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017;3(11):eaao4966.","journal-title":"Sci Adv"},{"key":"963_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","volume":"158","author":"F Xiao","year":"2020","unstructured":"Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831\u20133.","journal-title":"Gastroenterology"},{"key":"963_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.04.034","author":"H Zhang","year":"2020","unstructured":"Zhang H, Liao YS, Gong J, Liu J, Xia X, Zhang H. Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: a report of 164 cases. Dig Liver Dis. 2020. https:\/\/doi.org\/10.1016\/j.dld.2020.04.034.","journal-title":"Dig Liver Dis."},{"key":"963_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13121","author":"H Luxenburger","year":"2020","unstructured":"Luxenburger H, Sturm L, Biever P, Rieg S, Duerschmied D, Schultheiss M, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med. 2020. https:\/\/doi.org\/10.1111\/joim.13121.","journal-title":"J Intern Med."},{"key":"963_CR13","doi-asserted-by":"publisher","first-page":"110018","DOI":"10.1016\/j.mehy.2020.110018","volume":"143","author":"\u015e Ta\u015ftemur","year":"2020","unstructured":"Ta\u015ftemur \u015e, Ataseven H. Is it possible to use proton pump inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses. 2020;143:110018. https:\/\/doi.org\/10.1016\/j.mehy.2020.110018.","journal-title":"Med Hypotheses."},{"key":"963_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2558-4","author":"P Maisonnasse","year":"2020","unstructured":"Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2558-4.","journal-title":"Nature"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40261-020-00927-1","volume":"40","author":"S Das","year":"2020","unstructured":"Das S, Bhowmick S, Tiwari S, Sen S. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig. 2020;40:591\u2013601.","journal-title":"Clin Drug Investig"},{"key":"963_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014","author":"AB Cavalcanti","year":"2020","unstructured":"Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Coalition Covid-19 Brazil I Investigators, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2019014.","journal-title":"N Engl J Med."},{"issue":"11","key":"963_CR17","doi-asserted-by":"publisher","first-page":"e1916184","DOI":"10.1001\/jamanetworkopen.2019.16184","volume":"2","author":"KN Hayes","year":"2019","unstructured":"Hayes KN, Nakhla NR, Tadrous M. Further evidence to monitor long-term proton pump inhibitor use. JAMA Netw Open. 2019;2(11):e1916184.","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00963-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00963-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00963-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:05:52Z","timestamp":1628550352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00963-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00963-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"10 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was not supported by specific funds. It was conducted as part of our routine activity that is funded by Hospices Civils de Lyon and the University of Lyon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bruno Charpiat, Nathalie Bleyzac, and Michel Tod have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}